The Fourth Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou 310053, China.
Zhejiang Provincial Key Laboratory of Integrated Oncology and Intelligent Medicine, Hangzhou 310003, China.
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2024 Feb 1;53(1):131-139. doi: 10.3724/zdxbyxb-2023-0483.
To assess the value of serum alpha-fetoprotein (AFP), protein induced by vitamin K absence or antagonist-Ⅱ (PIVKA-Ⅱ) and glypican-3 (GPC-3) in the diagnosis of hepatocellular carcinoma (HCC).
Studies of AFP, PIVKA-Ⅱ, GPC-3 or in combination for the diagnosis of HCC since 2002 were searched in PubMed, Web of Science and Embase databases. The literature was screened according to the inclusion and exclusion criteria, the quality of the included articles was evaluated by QUADAS checklist, and relevant data were extracted by Meta DiSc, Review Manager 5.4 and Stata 15.1. The diagnostic values of AFP, PIVKA-Ⅱ and GPC-3 alone or in combination for HCC were assessed with receiver operating characteristic (ROC) curve.
A total of 32 articles were included in the study. Meta-analysis showed that when a single marker was used to diagnose HCC, the area under the ROC curve (AUC) of PIVKA-Ⅱ was the highest (0.88, 95%: 0.85-0.91), followed by GPC-3 and AFP. The AUC of combination of serum markers was higher than that of a single marker, and the AUC of PIVKA-Ⅱ combined with GPC-3 was the highest (0.90, 95%: 0.87-0.92). When a single marker was used for diagnosis, the sensitivity of PIVKA-Ⅱ and GPC-3 were relatively high (0.75 and 0.76), while the specificity of PIVKA-Ⅱ (0.88) and AFP (0.87) were higher than that of GPC-3 (0.81). The sensitivity of the combination of serum markers was higher than that of a single marker, while the specificity was not significantly improved. When a single marker is used to diagnose HCC, the diagnostic odds ratio (DOR) of PIVKA-Ⅱ was the highest (22, 95%: 13-36), followed by GPC-3 and AFP. The DOR of the combination of two markers in the diagnosis of HCC was higher than that of a single marker, and the DOR of AFP combined with GPC-3 was the highest (25, 95%: 9-67). The DOR of the combination of the three markers was significantly reduced to 10 (95%: 7-45).
When a single marker is used, PIVKA-Ⅱ has a higher diagnostic value for HCC. The combination of two markers can significantly improve the diagnostic sensitivity, and AFP combined with PIVKA-Ⅱ is recommended for the diagnosis of HCC. The combination of all three markers failed to further improve the diagnostic value.
评估血清甲胎蛋白(AFP)、维生素 K 拮抗剂-II 诱导蛋白(PIVKA-Ⅱ)和磷脂酰肌醇聚糖-3(GPC-3)在肝细胞癌(HCC)诊断中的价值。
检索 2002 年以来PubMed、Web of Science 和 Embase 数据库中关于 AFP、PIVKA-Ⅱ、GPC-3 或联合用于 HCC 诊断的研究。根据纳入和排除标准筛选文献,采用 QUADAS 清单评估纳入文章的质量,并使用 MetaDiSc、Review Manager 5.4 和 Stata 15.1 提取相关数据。采用受试者工作特征(ROC)曲线评估 AFP、PIVKA-Ⅱ和 GPC-3 单独或联合用于 HCC 的诊断价值。
共纳入 32 篇文章。Meta 分析结果显示,当使用单一标志物诊断 HCC 时,PIVKA-Ⅱ 的 ROC 曲线下面积(AUC)最高(0.88,95%:0.85-0.91),其次是 GPC-3 和 AFP。血清标志物联合的 AUC 高于单一标志物,且 PIVKA-Ⅱ联合 GPC-3 的 AUC 最高(0.90,95%:0.87-0.92)。当使用单一标志物进行诊断时,PIVKA-Ⅱ和 GPC-3 的敏感性相对较高(0.75 和 0.76),而 PIVKA-Ⅱ(0.88)和 AFP(0.87)的特异性高于 GPC-3(0.81)。血清标志物联合的敏感性高于单一标志物,特异性无显著提高。当使用单一标志物诊断 HCC 时,PIVKA-Ⅱ的诊断比值比(DOR)最高(22,95%:13-36),其次是 GPC-3 和 AFP。两种标志物联合诊断 HCC 的 DOR 高于单一标志物,且 AFP 联合 GPC-3 的 DOR 最高(25,95%:9-67)。三种标志物联合的 DOR 显著降低至 10(95%:7-45)。
当使用单一标志物时,PIVKA-Ⅱ对 HCC 具有较高的诊断价值。两种标志物联合可显著提高诊断灵敏度,推荐 AFP 联合 PIVKA-Ⅱ用于 HCC 诊断。三种标志物联合未能进一步提高诊断价值。